Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.

ABSTRACT:

Objective

Tesamorelin reduces visceral adipose tissue (VAT) in HIV. We investigated whether reductions in VAT with tesamorelin are associated with changes in alanine aminotransferase (ALT) and aspartate aminotransferase (AST).

Design and methods

We utilized data from two multicenter Phase III trials of tesamorelin among 806 HIV-infected patients with abdominal obesity. These studies showed that the majority of patients treated with tesamorelin are 'responders', defined a priori by the Food and Drug Administration as achieving at least 8% reduction in VAT. In the current analysis, we sought to examine the impact of VAT reduction on ALT and AST among patients participating in the Phase III trials with baseline elevated ALT or AST. Within this group, we compared changes in ALT

SUBMITTER: Fourman LT 

PROVIDER: S-EPMC5633509 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature